Hutchmed Share News (HCM)

Hutchmed partner gets European approval for fruqintinib

(Sharecast News) - Hutchmed China announced on Monday that its partner Takeda has received approval from the European Commission for 'Fruzaqla', or fruquintinib, as a monotherapy for adult patients with metastatic colorectal cancer (CRC).

IN BRIEF: Hutchmed China notes Takeda obtains EU approval for Fruzaqla

Hutchmed (China) Ltd - Hong Kong-headquartered biopharmaceutical company - Notes that Takeda Pharmaceuticals Co Ltd received a notification from the European Commission that it has approved Fruzaqla, alias fruquintinib, as a monotherapy for adults with metastatic colorectoral cancer who have been previously treated with available standard therapies. Takeda has the exclusive worldwide license to develop, commercialise and manufacture fruquintinib outside of mainland China.

Hutchmed celebrates "promising" results for sovleplenib in China

(Alliance News) - Hutchmed (China) Ltd on Monday said its phase 3 trial of sovleplenib showed "consistent benefits" in adults with autoimmune disorder primary immune thrombocytopenia or ITP.

Hutchmed publishes positive sovleplenib trial results

(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.

IN BRIEF: Hutchmed (China) begins trial of menin inhibitor HMPL-506

Hutchmed (China) Ltd - Hong Kong-headquartered biopharmaceutical company - Says that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hematological malignancies in China. The first patient received their first dose on May 31. "This is a Phase I, multicenter, open-label clinical study to evaluate the safety, pharmacokinetics and efficacy of HMPL-506 in patients with hematological malignancies. The study is divided into two phases, a dose escalation phase and a dose expansion phase. The study is expected to enroll at least 60 patients," Hutchmed says. HMPL-506 is a novel, investigational, selective small molecule inhibitor for oral administration targeting the menin protein, it explains.

IN BRIEF: Hutchmed China Simon To leaves role, succeeded by Dan Eldar

Hutchmed (China) Ltd - Hong Kong-headquartered biopharmaceutical company - Chair Simon To retires from his role as chair, succeeded by Dan Eldar, effective immediately. Former chair To agrees to serve as strategic advisor to Hutchmed and will continue to contribute to the company "on significant matters". In a separate release, the company highlights Sovleplenib phase 3 data in adult patients with primary immune thrombocytopenia who have received at least one prior line of standard therapy. ITP is an autoimmune disease characterised by a low platelet count, purpura, and hemorrhagic episodes caused by antiplatelet autoantibodies. Hutchmed will present the data in mid-June in Madrid.

Hutchmed announces trials of HMPL-306 and Surufatinib cancer therapies

(Alliance News) - Hutchmed (China) Ltd on Tuesday announced upcoming trials for two of its pipeline cancer treatments, both of which it believes could fill significant clinical gaps.

Hutchmed China launches two cancer treatment trials

(Sharecast News) - Hutchmed China announced the start of two significant clinical trials on Tuesday, aimed at addressing critical unmet needs in cancer treatment.

UK shareholder meetings calendar - next 7 days

Hutchmed notes CHMP's positive opinion for fruiquintinib approval

(Alliance News) - Hutchmed (China) Ltd on Friday said that its partner Takeda Pharmaceutical Co Ltd has been notified that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommends approval for fruquintinib.

Hutchmed China to make several presentations at cancer research meeting

(Sharecast News) - Hutchmed China announced the upcoming presentation of new and updated data from various studies featuring compounds it had discovered on Friday, at the American Association of Cancer Research (AACR) annual meeting from 5 to 10 April in San Diego, California.

Hutchmed endometrial cancer treatment gets priority review in China

(Sharecast News) - Hutchmed China announced the acceptance and granting of priority review by the China National Medical Products Administration (NMPA) for a new drug application combining fruquintinib and sintilimab for the treatment of advanced endometrial cancer on Tuesday.

Hutchmed endometrial cancer treatment application accepted for review

(Alliance News) - Hutchmed (China) Ltd on Tuesday jointly announced with Innovent Biologics that their new drug application for the combined fruquintinib and sintilimab treatment for endometrial cancer has been granted priority review by the China National Medical Products Administration.

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Hutchmed cancer treatment indication accepted for review in China

(Sharecast News) - Hutchmed China announced a significant milestone in its cancer treatment work on Thursday, with the supplemental new drug application (sNDA) for savolitinib had been accepted for review by the China National Medical Products Administration (NMPA).